EA202090634A1 - Антагонисты tim-3 для лечения и диагностики онкологических заболеваний - Google Patents
Антагонисты tim-3 для лечения и диагностики онкологических заболеванийInfo
- Publication number
- EA202090634A1 EA202090634A1 EA202090634A EA202090634A EA202090634A1 EA 202090634 A1 EA202090634 A1 EA 202090634A1 EA 202090634 A EA202090634 A EA 202090634A EA 202090634 A EA202090634 A EA 202090634A EA 202090634 A1 EA202090634 A1 EA 202090634A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tim3
- subject
- treatment
- peripheral blood
- positive cells
- Prior art date
Links
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 title abstract 8
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 title 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000771 oncological effect Effects 0.000 title 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 abstract 7
- 210000004027 cell Anatomy 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000005259 peripheral blood Anatomy 0.000 abstract 3
- 239000011886 peripheral blood Substances 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940124060 PD-1 antagonist Drugs 0.000 abstract 1
- 229940123803 TIM3 antagonist Drugs 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 210000004969 inflammatory cell Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
В настоящем документе предлагаются способы лечения субъекта, страдающего раком, включающие введение субъекту агониста TIM3 (например, анти-TIM3 антитела), одного или в сочетании с другим ингибитором иммунных контрольных точек (например, антагонистом PD-1), где субъект идентифицирован как имеющий высокую частоту TIM3-позитивных клеток (например, в инфильтрирующих опухоль воспалительных клетках) или растворимых TIM3 в периферической крови. Также предоставлены способы оценки эффективности лечения, включающего антагонист TIM3, у субъекта, страдающего раком, включающие измерение частоты TIM3 (и необязательно PD-1) позитивных клеток в определенных популяциях клеток и/или растворимого TIM3 в периферической крови субъекта, где высокая частота TIM3 (и необязательно PD-1) позитивных клеток и/или титр растворимого TIM3 в периферической крови субъекта указывает на ответную реакцию на лечение.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762551137P | 2017-08-28 | 2017-08-28 | |
PCT/US2018/048375 WO2019046321A1 (en) | 2017-08-28 | 2018-08-28 | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090634A1 true EA202090634A1 (ru) | 2020-06-17 |
Family
ID=63678676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090634A EA202090634A1 (ru) | 2017-08-28 | 2018-08-28 | Антагонисты tim-3 для лечения и диагностики онкологических заболеваний |
Country Status (13)
Country | Link |
---|---|
US (2) | US11787859B2 (ru) |
EP (1) | EP3676616A1 (ru) |
JP (1) | JP2020531854A (ru) |
KR (1) | KR20200044899A (ru) |
CN (1) | CN111094982A (ru) |
AU (1) | AU2018323462A1 (ru) |
BR (1) | BR112020003362A2 (ru) |
CA (1) | CA3078605A1 (ru) |
EA (1) | EA202090634A1 (ru) |
IL (2) | IL310079A (ru) |
MX (1) | MX2020001980A (ru) |
SG (1) | SG11202001211TA (ru) |
WO (1) | WO2019046321A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3400443B1 (en) * | 2016-01-04 | 2020-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma |
AU2017297506A1 (en) * | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
JP7274454B2 (ja) * | 2017-07-28 | 2023-05-16 | ブリストル-マイヤーズ スクイブ カンパニー | チェックポイント阻害薬のための予測末梢血バイオマーカー |
SG11202001211TA (en) | 2017-08-28 | 2020-03-30 | Bristol Myers Squibb Co | Tim-3 antagonists for the treatment and diagnosis of cancers |
CN113164601B (zh) * | 2019-09-19 | 2023-09-29 | 上药生物治疗(香港)有限公司 | 一种分离的抗原结合蛋白及其用途 |
CN113214396B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
WO2022165511A1 (en) * | 2021-01-29 | 2022-08-04 | Lapix Therapeutics, Inc. | Tartaric acid analogs and uses thereof |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
KR101846590B1 (ko) | 2010-06-11 | 2018-04-09 | 교와 핫꼬 기린 가부시키가이샤 | 항 tim-3 항체 |
WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
AU2013312211B2 (en) * | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
CN104072615B (zh) | 2014-01-26 | 2016-08-24 | 中国人民解放军军事医学科学院基础医学研究所 | 一种能阻断Tim-3信号通路的人Tim-3融合蛋白 |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CA2963935A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
EP3212231B1 (en) | 2014-10-27 | 2021-04-28 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
LT3215532T (lt) | 2014-11-06 | 2020-01-10 | F. Hoffmann-La Roche Ag | Anti-tim3 antikūnai ir jų naudojimo būdai |
WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
CN104592388B (zh) | 2015-03-02 | 2017-05-31 | 中国人民解放军总医院 | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 |
EP3265486A4 (en) | 2015-03-06 | 2018-11-14 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
WO2016186177A1 (ja) * | 2015-05-20 | 2016-11-24 | 大日本住友製薬株式会社 | Wt1抗原ペプチドおよび免疫調節剤の併用 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
EP3337826A1 (en) | 2015-08-20 | 2018-06-27 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
CN108139394B (zh) | 2015-10-02 | 2020-10-30 | 豪夫迈·罗氏有限公司 | 用于确定同时结合的基于细胞的fret测定法 |
WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
EP3400443B1 (en) * | 2016-01-04 | 2020-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma |
MD3443009T2 (ro) | 2016-04-12 | 2022-02-28 | Symphogen As | Anticorpi anti-TIM-3 și compoziții |
SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
AU2017297506A1 (en) | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
CN106632675A (zh) | 2016-12-15 | 2017-05-10 | 常州格露康生物医药科技有限公司 | 一种抗人Tim‑3单克隆抗体8E11及其制备方法 |
SG11202001211TA (en) | 2017-08-28 | 2020-03-30 | Bristol Myers Squibb Co | Tim-3 antagonists for the treatment and diagnosis of cancers |
-
2018
- 2018-08-28 SG SG11202001211TA patent/SG11202001211TA/en unknown
- 2018-08-28 AU AU2018323462A patent/AU2018323462A1/en active Pending
- 2018-08-28 MX MX2020001980A patent/MX2020001980A/es unknown
- 2018-08-28 IL IL310079A patent/IL310079A/en unknown
- 2018-08-28 JP JP2020512012A patent/JP2020531854A/ja active Pending
- 2018-08-28 BR BR112020003362-6A patent/BR112020003362A2/pt unknown
- 2018-08-28 EA EA202090634A patent/EA202090634A1/ru unknown
- 2018-08-28 CN CN201880055096.8A patent/CN111094982A/zh active Pending
- 2018-08-28 EP EP18773898.4A patent/EP3676616A1/en active Pending
- 2018-08-28 US US16/642,511 patent/US11787859B2/en active Active
- 2018-08-28 WO PCT/US2018/048375 patent/WO2019046321A1/en unknown
- 2018-08-28 KR KR1020207008660A patent/KR20200044899A/ko not_active Application Discontinuation
- 2018-08-28 CA CA3078605A patent/CA3078605A1/en active Pending
-
2020
- 2020-02-20 IL IL272821A patent/IL272821A/en unknown
-
2023
- 2023-09-08 US US18/463,743 patent/US20240117044A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019046321A1 (en) | 2019-03-07 |
CN111094982A (zh) | 2020-05-01 |
US20210171629A1 (en) | 2021-06-10 |
AU2018323462A1 (en) | 2020-03-26 |
CA3078605A1 (en) | 2019-03-07 |
MX2020001980A (es) | 2020-03-24 |
JP2020531854A (ja) | 2020-11-05 |
US20240117044A1 (en) | 2024-04-11 |
KR20200044899A (ko) | 2020-04-29 |
BR112020003362A2 (pt) | 2020-08-18 |
IL272821A (en) | 2020-04-30 |
EP3676616A1 (en) | 2020-07-08 |
US11787859B2 (en) | 2023-10-17 |
SG11202001211TA (en) | 2020-03-30 |
IL310079A (en) | 2024-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090634A1 (ru) | Антагонисты tim-3 для лечения и диагностики онкологических заболеваний | |
EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
MX2021011667A (es) | Anticuerpos contra icos. | |
CY1118551T1 (el) | Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4 | |
EA201792522A1 (ru) | Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4 | |
EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201890278A1 (ru) | Антитела к pd-l1 | |
EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
MX2023003418A (es) | Moleculas multiespecificas de union a antigenos y usos de estas. | |
EA201591716A1 (ru) | Антитела анти-il-33 и их применение | |
EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
EA201891292A1 (ru) | Мультиспецифические антитела | |
EA201590247A1 (ru) | Антитела к siglec-15 | |
BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
MX2017007537A (es) | Anticuerpos anti-pd-1 y sus metodos de uso. | |
UY37758A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
EA201790834A1 (ru) | Молекулы антител к pd-l1 и их применение | |
EA201501063A1 (ru) | СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
BR112016003394A2 (pt) | usos de um antagonista de pd-1 e um agonista do gitr e de um anticorpo biespecífico ou fragmento de ligação do antígeno do mesmo, e, combinação farmacêutica | |
EA201591331A1 (ru) | Антагонисты il-33 и их применение | |
EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
EA201691438A1 (ru) | Антитело, которое связывается с erbb-2 и erbb-3 |